SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 10, 2003

 

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

Oregon		0-22613		93-0797222
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(IRS Employer Identification Number)
One S.W. Columbia, Suite 1105 Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant’s telephone number, including area code

 

 

Item 5. Other Events and Regulation FD Disclosure.

 

The information set forth below pursuant to Item 12 shall also be deemed filed pursuant to Item 5.

 

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

 

Exhibit Number		Description
99.1		Press Release dated December 10, 2003 announcing presentation of preclinical date on AVI’s microbubble drug delivery and AVI’s NEUGENE® antisense anti-cancer strategies.

 

Item 12. Results of Operations and Financial Condition.

 

AVI BioPharma, Inc. (the “Company”) issued a press release on December 10, 2003, before the opening of trading in its Common Stock on the Nasdaq National Market System.  A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

 

The Press Release announced the presentation of preclinical date on AVI’s microbubble drug delivery and AVI’s NEUGENE^® antisense anti-cancer strategies.

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on December 15, 2003.

 

	AVI BioPharma, Inc.
	By:	/s/ ALAN P.TIMMINS
		Alan P. Timmins
		President and Chief Operating Officer (Principal Operating Officer)

 

2